• 1
    Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer—PFA-100™. Sem Thromb Hemost 1995; 21 (Suppl. 2): 10612.
  • 2
    Kundu SK, Heilmann E, Sio R, Garcia C, Ostgaart R. Characterization of an in vitro platelet function analyzer, PFA-100™. Clin Appl Thromb Hemost 1996; 2: 2419.
  • 3
    Fressinaud E, Veyradiers A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91: 132531.
  • 4
    Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 359.
  • 5
    Favoloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100™) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999; 62: 16574.
  • 6
    Dean J, Blanchette V, Carcao M, Stain A, Sparling C, Siekmann J, Turecek P, Lillicrap D, Rand M. von Willebrand disease in a pediatric-based population—comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000; 84: 4019.
  • 7
    Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti M. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999; 96: 2137.
  • 8
    Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1: 162836.
  • 9
    Quiroga T, Goycoolea M, Muñoz B, Morales M, Aranda E, Panes O, Pereira J, Mezzano D. Template bleeding time and PFA-100® have low sensitivity to screen patients with mucocutaneous haemorrhages of hereditary nature: comparative study in 148 patients. J Thromb Haemost 2004;